Abstracts tagged "Tuberculosis"

Abstract Number: 1153 • 2019 ACR/ARP Annual Meeting
Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population
Alice Fike¹, Yanira Ruiz-Perdomo ¹ and James Katz ¹, ¹NIAMS, BETHESDA, MD
Background/Purpose: The potential for reactivation of tuberculosis (TB) in patients treated with anti-TNF or other immunosuppressive agents has been well described. Interferon-gamma release assays (IGRA)…
Abstract Number: 1802 • 2019 ACR/ARP Annual Meeting
Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Urmi Khanna¹, Ariana Ellis ², AbdulAziz Galadari ³, Jeffery Hu ⁴, Josh Gallop ⁵, M. Elaine Husni ⁶ and Anthony Fernandez ⁷, ¹Department of Dermatology , Cleveland Clinic, Cleveland, OH, ²Northeast Ohio Medical University, Cleveland, OH, ³Cleveland Clinic, Abu Dhabi, Cleveland, ⁴Case Western Reserve University, Cleveland, ⁵Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ⁶Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁷Department of Dermatology and Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for repeat Latent Tuberculosis Infection (LTBI) testing while on biologics are not clearly defined. The American College of Rheumatology recommends repeat LTBI screening…
Abstract Number: 2097 • 2019 ACR/ARP Annual Meeting
Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
Ufuk İlgen¹, Sezin Turan ¹, Hakan Emmungil ¹, Alper Sarı ², Abdulsamet Erden ², Levent Kilic ³, Ömer Karadağ ², Sedat Kiraz ³, Ali İhsan Ertenli ⁴, Orhan Küçükşahin ⁵, Şükran Erten ⁶, Zeynel Abidin Akar ⁷, Burak Öz ⁷, Süleyman Serdar Koca ⁸, Cemal Bes ⁹, Nilufer Alpay-Kanitez ¹⁰, Emre Tekgöz ¹¹, Seda Çolak ¹¹, Muhammet Çınar ¹¹, Sedat Yılmaz ¹¹, Veli Yazısız ¹², Mustafa Ender Terzioğlu ¹², Ayşe Bahar Keleşoğlu Dinçer ¹³, Aşkın Ateş ¹³, Rıdvan Mercan ¹⁴, Onay Gercik ¹⁵, Servet Akar ¹⁶, Mehmet Pamir Atagündüz ¹⁷, Gezmiş Kimyon ¹⁸, Emel Gönüllü ¹⁹, Emine Duygu Ersözlü ²⁰, Müge Aydın Tufan ²¹, Burcu Yağız ²², Belkıs Nihan Coşkun ²³, Yavuz Pehlivan ²², Ediz Dalkılıç ²² and Umut Kalyoncu ²⁴, ¹Trakya University, Edirne, Turkey, ²Hacettepe University, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ⁵Liv Hospital, Ankara, Turkey, ⁶Yıldırım Beyazıt University, Ankara, Turkey, ⁷Fırat University, Elazığ, Turkey, ⁸Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁹University of Medical Sciences, İstanbul, Turkey, ¹⁰Koc University School of Medicine, Division of Rheumatology, İstanbul, Turkey, ¹¹University of Medical Sciences, Ankara, Turkey, ¹²Akdeniz University, Antalya, Turkey, ¹³Ankara University, Ankara, Turkey, ¹⁴Namık Kemal University, Tekirdağ, Turkey, ¹⁵Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁷Marmara University, İstanbul, Turkey, ¹⁸Mustafa Kemal University, Hatay, Turkey, ¹⁹Sakarya University, Sakarya, Turkey, ²⁰Adana State Hospital, Adana, Turkey, ²¹Başkent University, Adana, Turkey, ²²Uludağ University, Bursa, Turkey, ²³Uludağ University, Bursa, ²⁴Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Screening for and the treatment of latent tuberculosis is recommended in patients with inflammatory arthritides prior to biologic treatments, particularly the TNF inhibitors. The…
Abstract Number: 2098 • 2019 ACR/ARP Annual Meeting
Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas
Andrea Shimabuco ¹, Ana Cristina de Medeiros Ribeiro ², Renata Miossi ³, Karina Bonfiglioli ³, Julio Cesar Bertacini Moraes ³, Celio Gonçalves ³, Percival Sampaio-Barros ³, Claudia Goldenstein-Schainberg ³, Fernando Henrique Souza ³, Leandro Prado ³, Michelle Remião Ugolini-Lopes ⁴, Emily Yuki ⁵, Eloisa Bonfa ⁶ and Carla Gonçalves Schahin Saad³, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Despite late tuberculosis infection (LTBI) screening before anti-TNF treatment, TB reactivation/new exposure in endemic areas remains a relevant problem. The specific analysis of Ankylosing…
Abstract Number: 1324 • 2016 ACR/ARHP Annual Meeting
The Result of Follow-up Interferon-Gamma-Release Assays in Patients with Rheumatic Disease Receiving Biologic Agents in a Japanese Hospital
Yasuhiro Suyama¹, Haruki Sawada², Yukihiko Ikeda³, Rui Kawato⁴, Sakura Tamaki⁴, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Immune-Rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Active tuberculosis (TB) is one of the most devastating side effects of biologic agents use. Several guidelines for the prevention of biologic agents-related infections…
Abstract Number: 1350 • 2015 ACR/ARHP Annual Meeting
Multi-Targeted Loop-Mediated Isothermal Amplification for Rapid Diagnosis of Osteoarticular Tuberculosis in 60 Minutes: Experience from North India
Kusum Sharma¹, Aman Sharma² and Mandeep Dhillon³, ¹Department of Medical Microbiology,, PGIMER,, Chandigarh, India, ²Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Department of Ortho[aedics,, PGIMER,, Chandigarh, India
Background/Purpose: Loop-mediated Isothermal Amplification (LAMP) is a promising nucleic-acid amplification assay. Prompt and accurate diagnosis of Osteoarticular tuberculosis (OATB) is required for early treatment, better…
Abstract Number: 1364 • 2013 ACR/ARHP Annual Meeting
Detection of Latent Tuberculosis Infection in Rheumatologic Diseases Before Anti-TNFα Therapy: Tuberculin Skin Test Versus IFN-γ Assay
Suleyman Ozbek¹, Ismail Hanta², Sedat Kuleci³, Gulsah Seydaoglu³ and Ezgi Ozyilmaz³, ¹Division of Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey, ²Pulmonary, Cukurova University, Adana, Turkey, ³Cukurova University, Adana, Turkey
Background/Purpose: We aimed to evaluate tuberculin skin test (TST) and interferon-gamma (IFN-γ) test results for latent tuberculosis infection (LTBI) in patients with rheumatologic diseases prior…
Abstract Number: 1137 • 2013 ACR/ARHP Annual Meeting
Evaluating Indeterminate Quantiferon-TB Gold In-Tube Results in Patients With Chronic Inflammatory Diseases On Immunosuppressive Therapy
Cassandra Calabrese¹, Robert A. Overman^2,3, Stacie Dusetzina⁴ and Rula Hajj-Ali⁵, ¹Cleveland Clinic, Cleveland, OH, ²Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ³Rheumatology, Cleveland Clinic, Cleveland, OH, ⁴Epidemiology, School of Medicine and Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Raleigh-Durham, NC, ⁵Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: The Quantiferon test (QFT) is used to for screen for tuberculosis in patients with autoinflammatory conditions (IC) prior to the use of immunosuppressant medications. …
Abstract Number: 316 • 2013 ACR/ARHP Annual Meeting
Quantiferon-TB Test Can Be Usefull For Decision Of Anti-Tuberculosis Prophylaxis During Anti-TNF Treatment: Result Of Real Life
Umut Kalyoncu¹, Levent Kilic¹, Ahmet Cagkan Inkaya², Omer Karadag³, Sule Apras Bilgen⁴, Ali Akdogan⁴, Sedat Kiraz⁵ and Ihsan Ertenli³, ¹Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ²infectious disease, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ⁵Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Anti-tumor necrosis factor (TNF) treatments may increase tuberculosis. Most of the national guidelines recommend tuberculin skin test (TST) for screening of latent tuberculosis. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].